Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

<p>With the current pullback in its stock price, we are taking this opportunity to initiate a long position in <a href="https://www.smartkarma.com/entities/20664" target="_blank" data-smartkarma-citation="entities:20664:1">Kite Pharma Inc (KITE US)</a> , another mid-cap core position for our model portfolio. We looked at Kite's upcoming product pipeline and feel bullish about its next generation therapies in chimeric antigen receptor targeted T cells (CAR-T) space. Out first price target is $75 (based on rNPV of projected revenue in r/r DLBCL in the U.S., E.U.).</p>

With the current pullback in its stock price, we are taking this opportunity to initiate a long position in Kite Pharma Inc (KITE US) , another mid-cap core position for our model portfolio. We looked at Kite's upcoming product pipeline and feel bullish about its next generation therapies in chimeric antigen receptor targeted T cells (CAR-T) space. Out first price target is $75 (based on rNPV of projected revenue in r/r DLBCL in the U.S., E.U.).

Kite Pharma: 'Flying Higher' in Red-Hot Cancer Immune-Oncology Space.